


Sharp drop-off in new drugs approved

Approvals for new drugs dropped to a six-year low in 2016. Industry insiders are optimistic that the recently passed 21st Century Cures Act will speed up the process.

Novel drug approvals



—Food and Drug Administration

60%

Percentage of newly approved drugs in 2016 given fast-track or priority review because of medical significance

1,446


Company requests for fast-track review since 1998

70%

Percentage of fast-track requests granted since the program was established in 1998

98

Fast-track requests granted in the past year
—Food and Drug Administration



92%

Percentage of patients likely to choose a drug labeled as a “breakthrough” over one whose early results are comparable but not labeled as a “breakthrough”

—JAMA, 2016

94%

Percentage of physicians likely to prescribe a hypothetical “breakthrough” drug over a drug with “early promising results,” even though they were told the results in clinical trials were similar

—JAMA, 2016

106

Requests received by the FDA in fiscal 2016 for expedited review of new drugs as “breakthrough therapies”—a designation given to drugs with early promising results but not definitive proof of efficacy

46 Requests granted

—Food and Drug Administration